Magnetic Resonance Image-Guided Hypofractionated Ablative Radiation Therapy for Hepatocellular Carcinoma With Tumor Thrombus Extending to the Right Atrium


Creative Commons License

Dincer N., UĞURLUER G., Mustafayev T. Z., Gungor G., ATALAR B., GÜVEN K., ...Daha Fazla

CUREUS JOURNAL OF MEDICAL SCIENCE, cilt.14, sa.4, 2022 (ESCI) identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 14 Sayı: 4
  • Basım Tarihi: 2022
  • Doi Numarası: 10.7759/cureus.23981
  • Dergi Adı: CUREUS JOURNAL OF MEDICAL SCIENCE
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI)
  • Anahtar Kelimeler: mr-linac, sbrt, tumor thrombus, inoperable, hepatocellular cancer, LIVER, RADIOTHERAPY, RADIOEMBOLIZATION, REPRODUCIBILITY
  • Acıbadem Mehmet Ali Aydınlar Üniversitesi Adresli: Evet

Özet

Hepatocellular carcinoma (HCC) presenting with tumor thrombus and inferior vena cave (IVC)/right atrium (RA) infringement point to an advanced-stage disease that is deemed inoperable. Stereotactic body radiotherapy is an emerging treatment option for this group of patients with promising outcomes in recent studies that are comparable to conventional treatment methods, namely, transarterial chemoembolization and transarterial radioembolization. Here, we report a case of HCC with RA extension through the IVC. The patient was referred to our clinic for treatment options, and he was found suitable for magnetic resonance imaging-guided radiotherapy (MRgRT). We treated the patient with MRgRT in five fractions to a total dose of 40 Gray. The tumor was tracked during the treatment sessions, and adaptive treatment planning was performed before each fraction. The patient tolerated the treatment well with no acute grade 3-4 toxicities. The last follow-up showed that the patient had a complete biochemical response and is now a candidate for an orthotopic liver transplant. To our knowledge, this report is the first to document the MRgRT treatment of an HCC with TT and RA extension. MRgRT is safe and feasible for this patient group and can be an effective bridging therapy for liver transplants.